HC Wainwright reiterated their buy rating on shares of I-Mab (NASDAQ:IMAB - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $7.00 target price on the stock.
Separately, Needham & Company LLC upped their price target on I-Mab from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Friday, June 27th.
Get Our Latest Research Report on I-Mab
I-Mab Stock Performance
Shares of IMAB traded down $0.26 during trading hours on Wednesday, hitting $2.05. 392,373 shares of the company were exchanged, compared to its average volume of 395,220. The firm's 50 day moving average is $1.75 and its 200-day moving average is $1.20. I-Mab has a 52 week low of $0.60 and a 52 week high of $3.08.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. HBK Sorce Advisory LLC acquired a new position in I-Mab in the 1st quarter valued at $38,000. Ground Swell Capital LLC acquired a new position in I-Mab in the 1st quarter valued at $53,000. Millennium Management LLC grew its stake in I-Mab by 763.1% in the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock valued at $83,000 after buying an additional 86,424 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in I-Mab in the 4th quarter valued at $93,000. Finally, Cantor Fitzgerald L. P. acquired a new position in I-Mab in the 4th quarter valued at $119,000. 38.38% of the stock is currently owned by institutional investors and hedge funds.
About I-Mab
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Featured Stories
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
